

Tuesday, May 29, 2007

COMPANY PRESS RELEASE

Transgenomic, Inc. Launches Next Generation HANABI –PIII Metaphase Chromosome Harvester

Omaha, Neb, May 29 – Transgenomic, Inc. ([OTC BB: TBIO.OB](#)) announced today that it is launching the next generation HANABI-PIII Metaphase Chromosome Harvester at the Association of Genetic Technologists (“AGT”) meeting to be held in Denver, Colorado from May 31 through June 3, 2007. The HANABI-PIII Metaphase Chromosome Harvester has been developed specifically for Cytogenetics laboratories and can process up to 64 suspension cultures per run from blood or bone marrow samples. Cytogenetics is the study of the structure of chromosome material. It includes routing analysis of G-Banded chromosomes, other Cytogenetic banding techniques, as well as molecular Cytogenetics such as fluorescent in situ hybridization (“FISH”) and comparative genomic hybridization (“CGH”). The system greatly improves laboratory productivity by reliably automating the sample preparation process and providing consistent quality compared to manual methods.

The HANABI-PIII Metaphase Chromosome Harvester is the newest addition to Transgenomic’s Cytogenetics automation product line. It compliments the previously introduced HANABI-PII Metaphase Chromosome Harvester that processes up to 24 samples. Transgenomic is the exclusive distributor in North America and key markets in Europe and Asia for these products manufactured by ADScience Technologies.

In announcing the product launch, Craig Tuttle, Transgenomic’s President and Chief Executive Officer, commented, “We are very pleased to extend the HANABI Metaphase Chromosome Harvester product line and provide such a dynamic productivity tool for the Cytogenetics laboratory. This is an important addition to our product portfolio which is exemplified by our WAVE® System platforms and our emerging CLIA and GLP Clinical Reference Laboratory and Genomic Analysis and Research Services.”

To find out more about Transgenomic’s Cytogenetics automation offerings, go to www.transgenomic.com and click on Cytogenetics Automated Systems or contact Transgenomic at (888) 233-9382, +1 402 452 5400 or in Europe at +33 1 30 68 90 13.

About Transgenomic: A decade of discovery 1997 - 2007

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE® DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, and Transgenomic Discovery and CLIA Lab Services. Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.

Transgenomic Cautionary Statements

Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management’s current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.